212 related articles for article (PubMed ID: 32054487)
1. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
[TBL] [Abstract][Full Text] [Related]
2. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Baker R; Han G; Sarangkasiri S; DeMarco M; Turke C; Stevens CW; Dilling TJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):190-5. PubMed ID: 22929858
[TBL] [Abstract][Full Text] [Related]
3. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
[TBL] [Abstract][Full Text] [Related]
4. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
5. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.
Bongers EM; Botticella A; Palma DA; Haasbeek CJ; Warner A; Verbakel WF; Slotman B; Ricardi U; Senan S
Radiother Oncol; 2013 Oct; 109(1):95-9. PubMed ID: 24183862
[TBL] [Abstract][Full Text] [Related]
6. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
Ren C; Ji T; Liu T; Dang J; Li G
Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
[TBL] [Abstract][Full Text] [Related]
7. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients.
Meng Y; Yang H; Wang W; Tang X; Jiang C; Shen Y; Luo W
Radiat Oncol; 2019 Jan; 14(1):7. PubMed ID: 30642354
[TBL] [Abstract][Full Text] [Related]
8. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
[TBL] [Abstract][Full Text] [Related]
9. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
Parker SM; Siochi RA; Wen S; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.
Liu Y; Wang W; Shiue K; Yao H; Cerra-Franco A; Shapiro RH; Huang KC; Vile D; Langer M; Watson G; Bartlett G; Ai H; Sheski F; Jin JY; Zellars R; Fu P; Lautenschlaeger T; Kong FS
Radiother Oncol; 2021 Mar; 156():231-238. PubMed ID: 33096168
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
[TBL] [Abstract][Full Text] [Related]
15. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
[TBL] [Abstract][Full Text] [Related]
17. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
Yamaguchi S; Ohguri T; Ide S; Aoki T; Imada H; Yahara K; Narisada H; Korogi Y
Lung Cancer; 2013 Nov; 82(2):260-5. PubMed ID: 24054547
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]